Omeros OMER
NASDAQ OMER
$18.95 -0.16 (-0.84%)
At close: Sep 4, 2026 · 4:00 PM EDT

Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)

Omeros (OMER) posted Total Non-Current Liabilities of $202.1 million for Q1 2026, up 20.0% sequentially from $168.5 million in Q4 2025, and down 12.36% YoY from $230.7 million in Q1 2025.

Analysis

Omeros (OMER) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Omeros has reported Total Non-Current Liabilities for 6 years, with the latest figure at $202.1 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 12.36% year-over-year to $202.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202.1 million (down 12.36% YoY) and the FY2025 annual result came in at $168.5 million, down 38.2% from the prior year.
  • Total Non-Current Liabilities grew to $202.1 million in Q1 2026 per OMER's latest filing, from $168.5 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $590.5 million in Q4 2022 and troughed at $168.5 million in Q4 2025.
  • A 5-year average of $356.9 million and a median of $354.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities soared 52.88% in 2023, then slumped 47.02% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $590.5 million in 2022, then sank by 36.3% to $376.2 million in 2023, then retreated by 27.54% to $272.6 million in 2024, then sank by 38.2% to $168.5 million in 2025, then rose by 20.0% to $202.1 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $202.1 million, $168.5 million, and $181.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Omeros 1.38 Bn 1.38 Bn 27.73 Mn 282.97 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 282.97 Mn
Mar 31, 2026 265.48 Mn
Dec 31, 2025 289.69 Mn
Sep 30, 2025 401.68 Mn
Jun 30, 2025 424.75 Mn
Mar 31, 2025 444.21 Mn
Dec 31, 2024 455.19 Mn
Sep 30, 2024 464.41 Mn
Jun 30, 2024 478.82 Mn
Mar 31, 2024 506.73 Mn
Dec 31, 2023 401.16 Mn
Sep 30, 2023 507.02 Mn
Jun 30, 2023 506.42 Mn
Mar 31, 2023 504.74 Mn
Dec 31, 2022 504.84 Mn
Sep 30, 2022 502.87 Mn
Jun 30, 2022 377.38 Mn
Mar 31, 2022 373.27 Mn
Dec 31, 2021 394.37 Mn